Glucagon-like peptide-1 receptor agonists linked to a reduced risk of developing asthma among patients with type 2 diabetes
Yung-Sheng Cheng, Chi-Hsiang Chung, Shih-Ming Kuo, Chih-Ping Lin, Tsu-Hsuan Weng, Sheng-Chiang Su, Chieh-Hua Lu, Feng-Chih Kuo, Wu-Chien Chien, Yao-Jen Liang, Peng-Fei Li · 2025
Read Glucagon-like peptide-1 receptor agonists linked to a reduced risk of developing asthma among patients with type 2 diabetes by Yung-Sheng Cheng, Chi-Hsiang Chung, Shih-Ming Kuo, Chih-Ping Lin, Tsu-Hsuan Weng, Sheng-Chiang Su, Chieh-Hua Lu, Feng-Chih Kuo, Wu-Chien Chien, Yao-Jen Liang, Peng-Fei Li (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12712316.txt.
Description
Yung-Sheng Cheng and co-authors ask, in a 2025 study, whether a class of diabetes drugs also lowers the chance of developing asthma. The drugs act on a gut hormone receptor and may calm asthma-related immune paths. Using a national insurance database, the team followed over thirteen hundred treated patients with type 2 diabetes, none with prior asthma.
Treated patients developed asthma at about two-thirds the adjusted rate of untreated ones. The protective tilt held across severity tiers, from cases without attacks to the most dangerous form. Follow-up ran near three years on average. The authors read the pattern as a class effect worth testing in trials built for asthma outcomes.
Catalog record
| CREATOR | Yung-Sheng Cheng, Chi-Hsiang Chung, Shih-Ming Kuo, Chih-Ping Lin, Tsu-Hsuan Weng, Sheng-Chiang Su, Chieh-Hua Lu, Feng-Chih Kuo, Wu-Chien Chien, Yao-Jen Liang, Peng-Fei Li |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |